127 related articles for article (PubMed ID: 37823726)
1. Targeted single-cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis-resistant state in hematologic malignancies.
Shen X; Dong P; Kong J; Sun N; Wang F; Sang L; Xu Y; Zhang M; Chen X; Guo R; Wang S; Lin Q; Jiang Z; Xu S; Zhang C; Bian Z; Wang W; Guo R
Cell Biochem Funct; 2023 Dec; 41(8):1343-1356. PubMed ID: 37823726
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic
Osswald L; Hamarsheh S; Uhl FM; Andrieux G; Klein C; Dierks C; Duquesne S; Braun LM; Schmitt-Graeff A; Duyster J; Boerries M; Brummer T; Zeiser R
Mol Cancer Res; 2021 Sep; 19(9):1596-1608. PubMed ID: 34088868
[TBL] [Abstract][Full Text] [Related]
3. Integrated single-cell RNA-seq analysis identifies immune heterogeneity associated with KRAS/TP53 mutation status and tumor-sideness in colorectal cancers.
Liu X; Xu X; Wu Z; Shan Q; Wang Z; Wu Z; Ding X; Huang W; Wang Z
Front Immunol; 2022; 13():961350. PubMed ID: 36172359
[TBL] [Abstract][Full Text] [Related]
4. Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.
Lin TL; Nagata Y; Kao HW; Sanada M; Okuno Y; Huang CF; Liang DC; Kuo MC; Lai CL; Lee EH; Shih YS; Tanaka H; Shiraishi Y; Chiba K; Lin TH; Wu JH; Miyano S; Ogawa S; Shih LY
Haematologica; 2014 Jan; 99(1):28-36. PubMed ID: 23996483
[TBL] [Abstract][Full Text] [Related]
5. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
[No Abstract] [Full Text] [Related]
6. RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives.
Alawieh D; Cysique-Foinlan L; Willekens C; Renneville A
Blood Cancer J; 2024 Apr; 14(1):72. PubMed ID: 38658558
[TBL] [Abstract][Full Text] [Related]
7. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.
Kurtz SE; Eide CA; Kaempf A; Khanna V; Savage SL; Rofelty A; English I; Ho H; Pandya R; Bolosky WJ; Poon H; Deininger MW; Collins R; Swords RT; Watts J; Pollyea DA; Medeiros BC; Traer E; Tognon CE; Mori M; Druker BJ; Tyner JW
Proc Natl Acad Sci U S A; 2017 Sep; 114(36):E7554-E7563. PubMed ID: 28784769
[TBL] [Abstract][Full Text] [Related]
8. From iron chelation to overload as a therapeutic strategy to induce ferroptosis in hematologic malignancies.
Li J; Zhang W
Hematology; 2022 Dec; 27(1):1163-1170. PubMed ID: 36222350
[TBL] [Abstract][Full Text] [Related]
9. IDH mutations in cancer and progress toward development of targeted therapeutics.
Dang L; Yen K; Attar EC
Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
[TBL] [Abstract][Full Text] [Related]
10. Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.
Chang YI; You X; Kong G; Ranheim EA; Wang J; Du J; Liu Y; Zhou Y; Ryu MJ; Zhang J
Leukemia; 2015 Sep; 29(9):1847-56. PubMed ID: 25801914
[TBL] [Abstract][Full Text] [Related]
11. Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma.
Liu YH; Hu CM; Hsu YS; Lee WH
Cell Death Dis; 2022 Sep; 13(9):817. PubMed ID: 36151074
[TBL] [Abstract][Full Text] [Related]
12. Rapid mutational analysis of N-ras proto-oncogene in hematologic malignancies: study of 77 Greek patient.
Speletas M; Arvanitidi K; Tzoanopoulos D; Tsironidou V; Pardali E; Aggeli C; Tsapogas P; Kartalis G; Sideras P; Ritis K
Haematologica; 2001 Sep; 86(9):918-27. PubMed ID: 11532619
[TBL] [Abstract][Full Text] [Related]
13. The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing.
Ahuja HG; Foti A; Bar-Eli M; Cline MJ
Blood; 1990 Apr; 75(8):1684-90. PubMed ID: 2183888
[TBL] [Abstract][Full Text] [Related]
14. Hematologic Neoplasms Associated with Down Syndrome: Cellular and Molecular Heterogeneity of the Diseases.
Peroni E; Gottardi M; D'Antona L; Randi ML; Rosato A; Coltro G
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895004
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation.
Zhang J; Wang J; Liu Y; Sidik H; Young KH; Lodish HF; Fleming MD
Blood; 2009 Feb; 113(6):1304-14. PubMed ID: 19066392
[TBL] [Abstract][Full Text] [Related]
16. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.
Rocquain J; Carbuccia N; Trouplin V; Raynaud S; Murati A; Nezri M; Tadrist Z; Olschwang S; Vey N; Birnbaum D; Gelsi-Boyer V; Mozziconacci MJ
BMC Cancer; 2010 Aug; 10():401. PubMed ID: 20678218
[TBL] [Abstract][Full Text] [Related]
17. IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
Lin J; Yao DM; Qian J; Chen Q; Qian W; Li Y; Yang J; Wang CZ; Chai HY; Qian Z; Xiao GF; Xu WR
Ann Hematol; 2012 Apr; 91(4):519-25. PubMed ID: 21997850
[TBL] [Abstract][Full Text] [Related]
18. In silico RNA-seq and experimental analyses reveal the differential expression and splicing of EPDR1 and ZNF518B genes in relation to KRAS mutations in colorectal cancer cells.
Riffo-Campos ÁL; Castillo J; Vallet-Sánchez A; Ayala G; Cervantes A; López-Rodas G; Franco L
Oncol Rep; 2016 Dec; 36(6):3627-3634. PubMed ID: 27805251
[TBL] [Abstract][Full Text] [Related]
19. Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation.
Müller F; Lim JKM; Bebber CM; Seidel E; Tishina S; Dahlhaus A; Stroh J; Beck J; Yapici FI; Nakayama K; Torres Fernández L; Brägelmann J; Leprivier G; von Karstedt S
Cell Death Differ; 2023 Feb; 30(2):442-456. PubMed ID: 36443441
[TBL] [Abstract][Full Text] [Related]
20. Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice.
Staffas A; Karlsson C; Persson M; Palmqvist L; Bergo MO
Leukemia; 2015 May; 29(5):1032-40. PubMed ID: 25371176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
